COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,308 Articles (22,772 medRxiv, 8,536 bioRxiv)

Most recent first Previous |  Page 850: Articles 8491-8500  | Next

Androgen receptor polyQ alleles and COVID-19 severity in men: a replication study
Lopez-Rodriguez, R., Ruiz-Hornillos, J., Corton, M., Almoguera, B., Minguez, P., Perez-Tomas, M. E., Barreda-Sanchez, M., Mancebo, E., Ondo, L., Martinez-Ramas, A., Fernandez-Caballero, L., the STOP_Coronavirus Study Group, , Paz-Artal, E., Guillen-Navarro, E., Ayuso, C.
10.1101/2022.03.25.22271678 — Posted: 2022-04-02
Lessons from a pandemic
Eggli, Y., Rousson, V.
10.1101/2022.03.30.22273190 — Posted: 2022-04-02
Immunogenicity of Pfizer-BioNTech COVID-19 mRNA Primary Vaccination Series in Recovered Individuals Depends on Symptoms at Initial Infection.
Nantel, S., Bourdin, B., Adams, K., Carbonneau, J., Rabezanaha, H., Hamelin, M.-E., McCormack, D., Savard, P., Longtin, Y., Cheng, M., DeSerres, G., Corbeil, J., Gilca, V., Baz, M., Boivin, G., Quach, C., Decaluwe, H.
10.1101/2022.03.29.22272714 — Posted: 2022-04-02
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: a phase 1/2, randomized, placebo-controlled, observer-blinded trial
Song, J. Y., Choi, W. S., Heo, J. Y., Lee, J. S., Jung, D. S., Kim, S.-W., Park, K. H., Eom, J. S., Jeong, S. J., Lee, J., Kwon, K. T., Choi, H. J., Sohn, J. W., Kim, Y. K., Noh, J. Y., Kim, W. J., Roman, F., Ceregido, M. A., Solmi, F., Philippot, A., Walls, A. C., Carter, L., Veesler, D., King, N., Kim, H., Ryu, J. H., Lee, S. J., Park, Y. W., Park, H. k., Cheong, H. J.
10.1101/2022.03.30.22273143 — Posted: 2022-04-02
Spatial-CITE-seq: spatially resolved high-plex protein and whole transcriptome co-mapping
Liu, Y., Distasio, M., Su, G., Asashima, H., Enninful, A., Qin, X., Deng, Y., Bordignon, P., Cassano, M., Tomayko, M., Xu, M. L., Halene, S., Craft, J. E., Hafler, D. A., Fan, R.
10.1101/2022.04.01.486788 — Posted: 2022-04-02
Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: a retrospective cohort study
Bryushkova, E. A., Skatova, V. D., Mutovina, Z. Y., Zagrebneva, A. I., Fomina, D. S., Kruglova, T. S., Akopyan, A. A., Strazhesko, I. D., Lukyanov, S. A., Tkacheva, O. N., Lysenko, M. A., Chudakov, D. M.
10.1101/2022.03.31.22269942 — Posted: 2022-04-01
Omicron breakthrough infection drives cross-variant neutralization and memory B cell formation
Quandt, J., Muik, A., Salisch, N., Lui, B. G., Lutz, S., Krueger, K., Wallisch, A.-K., Adams-Quack, P., Bacher, M., Finlayson, A., Ozhelvaci, O., Vogler, I., Grikscheit, K., Hoehl, S., Goetsch, U., Ciesek, S., Tuereci, O., Sahin, U.
10.1101/2022.04.01.486695 — Posted: 2022-04-01
Convergence of immune escape strategies highlights plasticity of SARS-CoV-2 spike
Yu, X., Juraszek, J., Rutten, L., Bakkers, M. J. G., Blokland, S., van den Broek, N. J. F., Verwilligen, A. Y. W., Abeywickrema, P., Vingerhoets, J., Neefs, J.-M., Bakhash, S. A. M., Roychoudhury, P., Greninger, A., Sharma, S., Langedijk, J. P. M.
10.1101/2022.03.31.486561 — Posted: 2022-04-01
Potent Human Broadly SARS-CoV-2 Neutralizing IgA and IgG Antibodies Effective Against Omicron BA.1 and BA.2
Planchais, C., Fernandez, I., Bruel, T., Dias de Melo, G., Prot, M., Beretta, M., Guardado-Calvo, P., Dufloo, J., Molinos-Albert, L. M., Backovic, M., Chiaravalli, J., Giraud, E., Vesin, B., Conquet, L., Grzelak, L., Planas, D., Staropoli, I., Guivel-Benhassine, F., Boulle, M., Cervantes-Gonzalez, M., French COVID Cohort Study Group, , CORSER Study Group, , Ungeheuer, M.-N., Charneau, P., van der Werf, S., Agou, F., Dimitrov, J. D., Simon-Loriere, E., Bourhy, H., Montagutelli, X., Rey, F. A., Schwartz, O., Mouquet, H.
10.1101/2022.04.01.486719 — Posted: 2022-04-01
Recall of pre-existing cross-reactive B cell memory following Omicron breakthrough infection
Kaku, C. I., Bergeron, A. J., Ahlm, C., Normark, J., Sakharkar, M., Forsell, M. N., Walker, L. M.
10.1101/2022.04.01.486726 — Posted: 2022-04-01

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).